All In Biotech

Drug Trial Radar · NCT06224348

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 643 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

643

Actual

Start

Jan 18, 2024

Primary completion

Aug 21, 2025

Study completion Nov 1, 2025

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jan 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe atopic dermatitis (AD) with a history of inadequate response of topical treatment, on background topical corticosteroid (TCS) and/or topical calcineurin inhibitor (TCI). The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate to severe AD aged 12 years and older on background TCS and/or TCI. Study details include: At the end of the treatment period, participants will have an option to enter a separate study: the blinded extension study EFC17600 (ESTUARY). For participants not entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 44 weeks including a 2 to 4-week screening, a 24-week randomized double-blind period, and a 16-week safety follow-up. For participants entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 28 weeks including a 2 to 4-week screening and a 24-week randomized double-blind period. The total treatment duration will be up to 24 weeks. The total number of visits will be up to 10 visits (or 9 visits for those entering the blinded extension study EFC17600 (ESTUARY).

Conditions

  • Dermatitis Atopic

Interventions

  • AmlitelimabDrug

    Pharmaceutical form: Injection solution Route of administration: SC injection

  • PlaceboDrug

    Pharmaceutical form: injection solution Route of administration: SC injection

  • Topical corticosteroidsDrug

    Pharmaceutical form: Topical formulation Route of administration: Topical

  • Topical calcineurin inhibitorsDrug

    Pharmaceutical form: Topical formulation Route of administration: Topical

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EU, EU reference countries, and Japan: Proportion of participants with Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24Time frame: Week 24
  2. EU, EU reference countries, and Japan: Proportion of participants reaching 75% reduction from baseline in Eczema Area and Severity Index (EASI) score (EASI-75) at Week 24Time frame: Week 24
  3. US and US reference countries: Proportion of participants with vIGA-AD of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24Time frame: Week 24

Locations

167 sites in 14 countries. Site status is shown where the registry gives one.

  • Cahaba Dermatology & Skin Health Center- Site Number : 8401066

    Birmingham, Alabama

  • Johnson Dermatology- Site Number : 8401076

    Fort Smith, Arkansas

  • Encino Research Center- Site Number : 8401042

    Encino, California

  • Marvel Clinical Research- Site Number : 8401102

    Huntington Beach, California

  • LA Universal Research Center- Site Number : 8401064

    Los Angeles, California

  • Cura Clinical Research- Site Number : 8401141

    Palmdale, California

  • Integrative Skin Science and Research- Site Number : 8401275

    Sacramento, California

  • Southern California Dermatology- Site Number : 8401043

    Santa Ana, California

  • Skin Care Research - Hollywood- Site Number : 8401071

    Hollywood, Florida

  • Clever Medical Research- Site Number : 8401160

    Miami, Florida

  • Acevedo Clinical Research Associates- Site Number : 8401088

    Miami, Florida

  • Palm Springs Community Health Center- Site Number : 8401264

    Miami Lakes, Florida

  • Global Clinical Professionals (GCP)- Site Number : 8401045

    St. Petersburg, Florida

  • University of South Florida- Site Number : 8401070

    Tampa, Florida

  • Avita Clinical Research- Site Number : 8401073

    Tampa, Florida

  • Cleaver Medical Group- Site Number : 8401138

    Dawsonville, Georgia

  • NorthShore University HealthSystem - Skokie Hospital- Site Number : 8401038

    Skokie, Illinois

  • Dawes Fretzin Clinical Research- Site Number : 8401015

    Indianapolis, Indiana

  • BRCR Global Gretna- Site Number : 8401243

    Gretna, Louisiana

  • Velocity Clinical Research - New Orleans- Site Number : 8401155

    New Orleans, Louisiana

  • Oakland Medical Center- Site Number : 8401116

    Troy, Michigan

  • Allergy & Immunology Associates of Ann Arbor- Site Number : 8401078

    Ypsilanti, Michigan

  • Dermatology and Skin Cancer Lee's Summit- Site Number : 8401157

    Lee's Summit, Missouri

  • Skin Specialists- Site Number : 8401068

    Omaha, Nebraska

  • Jubilee Clinical Research- Site Number : 8401054

    Las Vegas, Nevada

  • Allcutis Research - Portsmouth- Site Number : 8401082

    Portsmouth, New Hampshire

  • Equity Medical- Site Number : 8401239

    New York, New York

  • Icahn School of Medicine at Mount Sinai- Site Number : 8401129

    New York, New York

  • OptiSkin- Site Number : 8401163

    New York, New York

  • Apex Clinical Research Center- Site Number : 8401237

    Mayfield Heights, Ohio

  • Essential Medical Research- Site Number : 8401183

    Tulsa, Oklahoma

  • Vial Health - DermDox Dermatology- Site Number : 8401031

    Camp Hill, Pennsylvania

  • Clinical Research Center of the Carolinas- Site Number : 8401067

    Charleston, South Carolina

  • SMS Clinical Research- Site Number : 8401182

    Mesquite, Texas

  • Sienna Dermatology- Site Number : 8401148

    Missouri City, Texas

  • Texas Dermatology and Laser Specialists- Site Number : 8401131

    San Antonio, Texas

  • Discovery Clinical Trials - San Antonio - Stone Oak Parkway- Site Number : 8401026

    San Antonio, Texas

  • Complete Dermatology - Sugar Land- Site Number : 8401061

    Sugar Land, Texas

  • Cope Family Medicine - Ogden Clinic- Site Number : 8401114

    Bountiful, Utah

  • Tanner Clinic - Layton Antelope A- Site Number : 8401151

    Layton, Utah

Showing 40 of 167 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.